Yu.V. Gumenetskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu.V. Gumenetskaya has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Ю. В. Гуменецкая
Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «НМИЦ радиологии» Минздрава России
8 shared publications- Andrei Dmitrievich Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
6 shared publications - Sergey Anatolyevich Ivanov
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
6 shared publications - K. S. Makarova
A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
5 shared publications - Oleg B. Karyakin
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
5 shared publications - T. A. Kireeva
A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
5 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (6) , 91-98
Radiation therapy after radical prostatectomy: unresolved issues illustrated by clinical cases
Background. Despite advances and improvements in diagnostic and treatment methods, prostate cancer (PC) continues to be one of the most prevalent malignancies in men. The main treatment modalities for patients with localized and locally advanced PC are radical prostatectomy (RP), radiation therapy, and hormone therapy. After surgery, postoperative conformal external beam radiation therapy (EBRT) may be required in more than half of cases, taking into account individual risk factors. Discussion . Currently, there is an ongoing discussion regarding the indications and optimal timing of radiation therapy after RP: whether it should be administered in the adjuvant setting (i.e., when there is no disease recurrence, but unfavorable prognostic factors are present), or as so-called salvage radiation therapy, in cases of biochemical recurrence or macroscopically detectable tumors. We analyzed the most well-known international studies devoted to this issue. The lack of convincing data supporting the benefit of adjuvant EBRT in improving survival after RP, even in the presence of unfavorable factors, contributes to the ongoing debate about its appropriateness, given the known increased risk of treatment-related complications and the deterioration in patients’ quality of life. Clinical case descriptions. We present clinical cases illustrating the use of both adjuvant and salvage radiation therapy. Conclusion. After radical prostatectomy, adjuvant radiation therapy may be recommended for patients with unfavorable risk factors for recurrence. However, salvage radiation therapy reduces the risk of treatment-related complications, allows for dose escalation, and in nearly half of cases, helps avoid unnecessary and costly treatment.
- 13 January 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (6) , 91-98
Open AccessRadiation therapy after radical prostatectomy: unresolved issues illustrated by clinical cases
Background. Despite advances and improvements in diagnostic and treatment methods, prostate cancer (PC) continues to be one of the most prevalent malignancies in men. The main treatment modalities for patients with localized and locally advanced PC are radical prostatectomy (RP), radiation therapy, and hormone therapy. After surgery, postoperative conformal external beam radiation therapy (EBRT) may be required in more than half of cases, taking into account individual risk factors. Discussion . Currently, there is an ongoing discussion regarding the indications and optimal timing of radiation therapy after RP: whether it should be administered in the adjuvant setting (i.e., when there is no disease recurrence, but unfavorable prognostic factors are present), or as so-called salvage radiation therapy, in cases of biochemical recurrence or macroscopically detectable tumors. We analyzed the most well-known international studies devoted to this issue. The lack of convincing data supporting the benefit of adjuvant EBRT in improving survival after RP, even in the presence of unfavorable factors, contributes to the ongoing debate about its appropriateness, given the known increased risk of treatment-related complications and the deterioration in patients’ quality of life. Clinical case descriptions. We present clinical cases illustrating the use of both adjuvant and salvage radiation therapy. Conclusion. After radical prostatectomy, adjuvant radiation therapy may be recommended for patients with unfavorable risk factors for recurrence. However, salvage radiation therapy reduces the risk of treatment-related complications, allows for dose escalation, and in nearly half of cases, helps avoid unnecessary and costly treatment.
- Open Access
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 190-197
Radiation therapy for locally advanced thymoma. A case report
Thymoma is a tumor originating from the epithelial cells of the thymus. In cases when complete removal of the tumor is not possible due to its local spread, induction therapy, including chemotherapy, radiotherapy, or chemoradiotherapy, is administered to improve respectability.Case presentation. We present a case of a 41-year-old male who was diagnosed with IVA type B3 thymoma (cT3N0M1a) in March 2022. Computed tomography (18.02.22) revealed a tumor in the anterior mediastinum measuring 12.0×8.0×14.5 cm with spread to the right lung and pericardium, compression of large vessels; single nodular lesions along the pleura. From 19.03.22 to 26.05.22, 4 cycles of polychemotherapy with CAP were administered. From 9.08.22 to 24.11.22, 6 cycles of chemotherapy with etoposide + cisplatin were administered. Stable disease was observed. In January, 2023, the patient visited A. Tsyb MRRC for a consultation with oncologists. Surgery was not considered as a suitable treatment option due to the spread of the disease, and radiation therapy was recommended. From 16.02.23 to 3.04.23, a conformal external beam radiation therapy was delivered to a mediastinal tumor to a total dose of 60 Gy. The treatment was well tolerated. A control examination showed tumor size reduction meaning the tumor can be surgically removed. Considering positive response to radiation therapy, satisfactory performance status and age of the patient, a decision to perform surgery was made. On September 15, 2023 the mediastinal tumor was removed with pericardial resection and its reconstruction, upper and middle lobectomy, and precision removal of parietal pleural lesions. A follow-up examination (October 2024) revealed disease progression with the appearance of nodular lesions along the diaphragmatic pleura on the right. Chemotherapy with pemetrexed was administered. Currently, the performance status of the patient is satisfactory and he is socially active.Conclusion. Induction chemotherapy and radiotherapy for locally advanced unresectable thymoma can increase the feasibility of achieving complete tumor resection, thus improving treatment outcomes. The rarity of these tumors and the lack of standard approaches to the treatment of locally advanced thymic carcinomas determine the relevance of the problem and the need to make an optimal decision on treatment tactics in each specific clinical case.
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 190-197
Open AccessRadiation therapy for locally advanced thymoma. A case report
Thymoma is a tumor originating from the epithelial cells of the thymus. In cases when complete removal of the tumor is not possible due to its local spread, induction therapy, including chemotherapy, radiotherapy, or chemoradiotherapy, is administered to improve respectability.Case presentation. We present a case of a 41-year-old male who was diagnosed with IVA type B3 thymoma (cT3N0M1a) in March 2022. Computed tomography (18.02.22) revealed a tumor in the anterior mediastinum measuring 12.0×8.0×14.5 cm with spread to the right lung and pericardium, compression of large vessels; single nodular lesions along the pleura. From 19.03.22 to 26.05.22, 4 cycles of polychemotherapy with CAP were administered. From 9.08.22 to 24.11.22, 6 cycles of chemotherapy with etoposide + cisplatin were administered. Stable disease was observed. In January, 2023, the patient visited A. Tsyb MRRC for a consultation with oncologists. Surgery was not considered as a suitable treatment option due to the spread of the disease, and radiation therapy was recommended. From 16.02.23 to 3.04.23, a conformal external beam radiation therapy was delivered to a mediastinal tumor to a total dose of 60 Gy. The treatment was well tolerated. A control examination showed tumor size reduction meaning the tumor can be surgically removed. Considering positive response to radiation therapy, satisfactory performance status and age of the patient, a decision to perform surgery was made. On September 15, 2023 the mediastinal tumor was removed with pericardial resection and its reconstruction, upper and middle lobectomy, and precision removal of parietal pleural lesions. A follow-up examination (October 2024) revealed disease progression with the appearance of nodular lesions along the diaphragmatic pleura on the right. Chemotherapy with pemetrexed was administered. Currently, the performance status of the patient is satisfactory and he is socially active.Conclusion. Induction chemotherapy and radiotherapy for locally advanced unresectable thymoma can increase the feasibility of achieving complete tumor resection, thus improving treatment outcomes. The rarity of these tumors and the lack of standard approaches to the treatment of locally advanced thymic carcinomas determine the relevance of the problem and the need to make an optimal decision on treatment tactics in each specific clinical case.
- Open Access
- 13 May 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (1) , 76-84-84
Combined radiotherapy and hormone therapy in unfavorable intermediate risk prostate cancer
Background. Currently, the group of intermediate risk prostate cancer (PC) includes 2 subgroups - favorable and unfavorable intermediate risk according to the National Comprehensive Cancer Network (NCCN) classification. The optimal scope of therapy is not defined for the unfavorable intermediate risk subgroup. In particular, the need for and duration of hormone therapy (HT) during combined radiotherapy (CRT) have not yet been determined.Aim. To perform a comparative analysis of the efficacy and toxicity of CRT in patients with unfavorable intermediate risk treated with and without HT.Materials and methods. Eighty-four (84) patients with unfavorable intermediate risk PC were treated with CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center between May 2016 and December 2020. Patients were divided into two groups: external beam radiation therapy + brachytherapy (n = 40) and external beam radiation therapy + brachytherapy + HT (n = 44). Conformal external beam radiation therapy was delivered with conventional fractionation to a total dose of 44-46 Gy and the 192Ir high-dose rate brachytherapy was delivered with a single fraction of 15 Gy. Median duration of HT consisting of gonadotropin-releasing hormone agonist was 6 months. Median age was 65.2 years (range: 49-80 years). Median follow-up was 58.1 months (range: 18.6-83.7 months).Results. With a median follow-up of 4.8 years, progression-free survival was 95 % and 97.6 % in the external beam radiation therapy + brachytherapy group and external beam radiation therapy + brachytherapy + HT group, respectively (p = 0.578). The break between treatment stages of more than 28 days was associated with a statistically significant increase in the risk of PC recurrence (p = 0.007). Overall survival for the external beam radiation therapy + brachytherapy group versus external beam radiation therapy + brachytherapy + HT group was 97.5 and 93.2 % (p = 0.376), respectively.Late genitourinary toxicity was grade I in 8 (9.5 %) patients and grade II in 1 (1.2 %) patient. Urethral stricture developed in 3 (3.6 %) patients. Late gastrointestinal toxicity was grade I in 7 (8.3 %) patients and grade II in 1 (1.2 %) patient. There were no statistically significant differences in the incidence of late complications between groups with and without HT. There was a statistically significant (p = 0.049) effect of prostate volume on the incidence of late radiation proctitis.Conclusion. There were no statistically significant differences in progression-free survival and overall survival in patients with unfavorable intermediate risk PC who received external beam radiation therapy + brachytherapy with or without HT. The incidence and severity of adverse events were acceptable and allowed patients with PC to maintain high quality of life.
- 13 May 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (1) , 76-84-84
Open AccessCombined radiotherapy and hormone therapy in unfavorable intermediate risk prostate cancer
Background. Currently, the group of intermediate risk prostate cancer (PC) includes 2 subgroups - favorable and unfavorable intermediate risk according to the National Comprehensive Cancer Network (NCCN) classification. The optimal scope of therapy is not defined for the unfavorable intermediate risk subgroup. In particular, the need for and duration of hormone therapy (HT) during combined radiotherapy (CRT) have not yet been determined.Aim. To perform a comparative analysis of the efficacy and toxicity of CRT in patients with unfavorable intermediate risk treated with and without HT.Materials and methods. Eighty-four (84) patients with unfavorable intermediate risk PC were treated with CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center between May 2016 and December 2020. Patients were divided into two groups: external beam radiation therapy + brachytherapy (n = 40) and external beam radiation therapy + brachytherapy + HT (n = 44). Conformal external beam radiation therapy was delivered with conventional fractionation to a total dose of 44-46 Gy and the 192Ir high-dose rate brachytherapy was delivered with a single fraction of 15 Gy. Median duration of HT consisting of gonadotropin-releasing hormone agonist was 6 months. Median age was 65.2 years (range: 49-80 years). Median follow-up was 58.1 months (range: 18.6-83.7 months).Results. With a median follow-up of 4.8 years, progression-free survival was 95 % and 97.6 % in the external beam radiation therapy + brachytherapy group and external beam radiation therapy + brachytherapy + HT group, respectively (p = 0.578). The break between treatment stages of more than 28 days was associated with a statistically significant increase in the risk of PC recurrence (p = 0.007). Overall survival for the external beam radiation therapy + brachytherapy group versus external beam radiation therapy + brachytherapy + HT group was 97.5 and 93.2 % (p = 0.376), respectively.Late genitourinary toxicity was grade I in 8 (9.5 %) patients and grade II in 1 (1.2 %) patient. Urethral stricture developed in 3 (3.6 %) patients. Late gastrointestinal toxicity was grade I in 7 (8.3 %) patients and grade II in 1 (1.2 %) patient. There were no statistically significant differences in the incidence of late complications between groups with and without HT. There was a statistically significant (p = 0.049) effect of prostate volume on the incidence of late radiation proctitis.Conclusion. There were no statistically significant differences in progression-free survival and overall survival in patients with unfavorable intermediate risk PC who received external beam radiation therapy + brachytherapy with or without HT. The incidence and severity of adverse events were acceptable and allowed patients with PC to maintain high quality of life.
- Open Access
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 111-125
Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer
Purpose of the study. Generalization of the world experience of organ‑preserving treatment in muscle‑invasive bladder cancerMaterials and methods. The literature was searched in Medline, Cochrane Library, Elibrary and PubMed systems. Publications describing the modern possibilities of organ‑preserving treatment of muscle‑invasive bladder cancer were included, 58 of which were used to write this review.Results. The review highlights the results of international randomized and significant non‑randomized studies of organ‑preserving treatment in muscle‑invasive bladder cancer. Special attention is paid to the description of a modern combination of treatment methods to achieve its maximum effectiveness while maintaining the quality of life of patients. The analysis of the world literature was carried out, confirming the prospects of organ‑preserving treatment with careful selection of patients.Conclusion. Organ-preserving trimodal therapy for muscle‑invasive bladder cancer remains an alternative treatment strategy. Careful selection of patients plays a key role. The modern approach to trimodal therapy (TMT) is as follows: complete transurethral resection of the bladder (TURB), neoadjuvant or adjuvant chemotherapy, subsequent assessment of the response to treatment (re‑staging with TURB) should be performed; with a complete pathomorphological response, a course of remote radiation therapy up to TFD 60–66 Gy in the case of traditional fractionation (focal radiation therapy and the use of hypofractionation modes are also possible), using modern irradiation technologies (IGRT, IMRT). In case of an incomplete response, the implementation of the radical cystectomy (RCE) is shown. If a relapse occurs during follow‑up after treatment in the volume of TMT, a life‑saving RCE is shown.If the above conditions are met, the oncological results of treatment with TMT are equivalent to those during RCE, but require further study.
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 111-125
Open AccessTrimodal organ‑preserving treatment of muscle‑invasive bladder cancer
Purpose of the study. Generalization of the world experience of organ‑preserving treatment in muscle‑invasive bladder cancerMaterials and methods. The literature was searched in Medline, Cochrane Library, Elibrary and PubMed systems. Publications describing the modern possibilities of organ‑preserving treatment of muscle‑invasive bladder cancer were included, 58 of which were used to write this review.Results. The review highlights the results of international randomized and significant non‑randomized studies of organ‑preserving treatment in muscle‑invasive bladder cancer. Special attention is paid to the description of a modern combination of treatment methods to achieve its maximum effectiveness while maintaining the quality of life of patients. The analysis of the world literature was carried out, confirming the prospects of organ‑preserving treatment with careful selection of patients.Conclusion. Organ-preserving trimodal therapy for muscle‑invasive bladder cancer remains an alternative treatment strategy. Careful selection of patients plays a key role. The modern approach to trimodal therapy (TMT) is as follows: complete transurethral resection of the bladder (TURB), neoadjuvant or adjuvant chemotherapy, subsequent assessment of the response to treatment (re‑staging with TURB) should be performed; with a complete pathomorphological response, a course of remote radiation therapy up to TFD 60–66 Gy in the case of traditional fractionation (focal radiation therapy and the use of hypofractionation modes are also possible), using modern irradiation technologies (IGRT, IMRT). In case of an incomplete response, the implementation of the radical cystectomy (RCE) is shown. If a relapse occurs during follow‑up after treatment in the volume of TMT, a life‑saving RCE is shown.If the above conditions are met, the oncological results of treatment with TMT are equivalent to those during RCE, but require further study.
- Open Access
- 3 March 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 144-150
Proton therapy in the treatment of diffuse astrocytoma of the brain stem. Case report
Background. Despite the fact that cerebral astrocytoma belongs to low-grade tumors (grade II gliomas), it often leads to disability and death of patients. The localization of the tumor determines the severity of the clinical symptoms of the disease, which significantly affects its prognosis. The choice of the optimal treatment strategy for astrocytoma localized in the brain stem poses challenges and enables the vast majority of patients to be classified as inoperable. Therefore, radiation therapy or chemoradiotherapy are the main treatment modalities for patients with low-grade glioma. The location of the tumor in close proximity to vital centers makes radiation therapy planning difficult., because the delivery of high doses of radiation can cause serious treatment complications.Description of the clinical case. We present a clinical case of a successful treatment of a young, 20-year-old male patient with diffuse astrocytoma of the brain stem. As radical surgery was impossible to be performed, the patient was offered radiation therapy. The morphology, size, and location of the primary tumor posed challenges for selecting an optimal treatment strategy due to a high risk of damage to vital centers, which could lead to disability and even death of the patient. The use of proton therapy made it possible to deliver the maximum allowable dose of radiation to the tumor, limiting radiation exposure to surrounding healthy tissues. The patient received the complete course of proton therapy. After 36 months of follow-up, no complications and signs of disease progression were found.Conclusion. Despite the high risk of treatment complications, the use of proton therapy made it possible to complete the planned course of treatment, achieve tumor stabilization and significantly improve the life quality of the patient.
- 3 March 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (1) , 144-150
Open AccessProton therapy in the treatment of diffuse astrocytoma of the brain stem. Case report
Background. Despite the fact that cerebral astrocytoma belongs to low-grade tumors (grade II gliomas), it often leads to disability and death of patients. The localization of the tumor determines the severity of the clinical symptoms of the disease, which significantly affects its prognosis. The choice of the optimal treatment strategy for astrocytoma localized in the brain stem poses challenges and enables the vast majority of patients to be classified as inoperable. Therefore, radiation therapy or chemoradiotherapy are the main treatment modalities for patients with low-grade glioma. The location of the tumor in close proximity to vital centers makes radiation therapy planning difficult., because the delivery of high doses of radiation can cause serious treatment complications.Description of the clinical case. We present a clinical case of a successful treatment of a young, 20-year-old male patient with diffuse astrocytoma of the brain stem. As radical surgery was impossible to be performed, the patient was offered radiation therapy. The morphology, size, and location of the primary tumor posed challenges for selecting an optimal treatment strategy due to a high risk of damage to vital centers, which could lead to disability and even death of the patient. The use of proton therapy made it possible to deliver the maximum allowable dose of radiation to the tumor, limiting radiation exposure to surrounding healthy tissues. The patient received the complete course of proton therapy. After 36 months of follow-up, no complications and signs of disease progression were found.Conclusion. Despite the high risk of treatment complications, the use of proton therapy made it possible to complete the planned course of treatment, achieve tumor stabilization and significantly improve the life quality of the patient.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (2)
Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer
Применение сочетанной лучевой терапии (СЛТ) позволяет повысить эффективность лечения рака предстательной железы (РПЖ) у больных высокого онкологического риска. Остается неясным, имеет ли какое-либо преимущество включение в область облучения регионарных лимфоколлекторов с профилактической целью, поскольку эскалация дозы, как и увеличение объема облучения, сопряжены с высоким риском развития лучевых осложнений, которые, как известно, негативно влияют на качество жизни пациентов. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение влияния профилактического облучения лимфатических узлов малого таза на непосредственные результаты лечения, а также на качество жизни больных РПЖ высокого онкологического риска. МАТЕРИАЛ И МЕТОДЫ В период с ноября 2019 по январь 2021 г. в МРНЦ им. А.Ф. Цыба 60 больным РПЖ в объеме гормонолучевого лечения выполнена СЛТ. Пациенты были рандомизированы в две группы: с облучением регионарных лимфоколлекторов (n=32) и без их облучения (n=28). На первом этапе лечения проведен курс конформной дистанционной лучевой терапии до суммарной очаговой дозы 46 Гр. На втором этапе однократно выполнен сеанс высокомощностной брахитерапии (192Ir) в разовой очаговой дозе 15 Гр. РЕЗУЛЬТАТЫ Развитие острого лучевого цистита 1-й степени тяжести отмечено у 11 (34,4%) больных 1-й группы и у 12 (42,9%) пациентов 2-й (p=0,83). Во 2-й группе у 1 (3,6%) пациента отмечен острый лучевой цистит 2-й степени тяжести. Острый лучевой ректит 1-й степени тяжести наблюдался у 13 (40,6%) пациентов 1-й группы и у 3 (10,7%) 2-й (p=0,01) группы. ЗАКЛЮЧЕНИЕ Предварительный анализ исследования показал увеличение частоты развития лучевых реакций в группе пациентов с профилактическим облучением регионарных лимфоколлекторов.
- 1 January 2022
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 11 (2)
Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer
Применение сочетанной лучевой терапии (СЛТ) позволяет повысить эффективность лечения рака предстательной железы (РПЖ) у больных высокого онкологического риска. Остается неясным, имеет ли какое-либо преимущество включение в область облучения регионарных лимфоколлекторов с профилактической целью, поскольку эскалация дозы, как и увеличение объема облучения, сопряжены с высоким риском развития лучевых осложнений, которые, как известно, негативно влияют на качество жизни пациентов. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение влияния профилактического облучения лимфатических узлов малого таза на непосредственные результаты лечения, а также на качество жизни больных РПЖ высокого онкологического риска. МАТЕРИАЛ И МЕТОДЫ В период с ноября 2019 по январь 2021 г. в МРНЦ им. А.Ф. Цыба 60 больным РПЖ в объеме гормонолучевого лечения выполнена СЛТ. Пациенты были рандомизированы в две группы: с облучением регионарных лимфоколлекторов (n=32) и без их облучения (n=28). На первом этапе лечения проведен курс конформной дистанционной лучевой терапии до суммарной очаговой дозы 46 Гр. На втором этапе однократно выполнен сеанс высокомощностной брахитерапии (192Ir) в разовой очаговой дозе 15 Гр. РЕЗУЛЬТАТЫ Развитие острого лучевого цистита 1-й степени тяжести отмечено у 11 (34,4%) больных 1-й группы и у 12 (42,9%) пациентов 2-й (p=0,83). Во 2-й группе у 1 (3,6%) пациента отмечен острый лучевой цистит 2-й степени тяжести. Острый лучевой ректит 1-й степени тяжести наблюдался у 13 (40,6%) пациентов 1-й группы и у 3 (10,7%) 2-й (p=0,01) группы. ЗАКЛЮЧЕНИЕ Предварительный анализ исследования показал увеличение частоты развития лучевых реакций в группе пациентов с профилактическим облучением регионарных лимфоколлекторов.
- Open Access
- 10 December 2021
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 17 (4) , 94-99-99
Combinatorial radiation therapy for prostate cancer with seminal vesicle invasion
Background. It seems advisable to investigate the feasibility of radiation therapy combined with hormone therapy to treat locally advanced prostate cancer. Combination of two ways to deliver ionizing radiation doses enables us to elevate a total tumor dose and to reduce radiation exposure to critical organs. However, the feasibility of combinatorial radiation therapy (CRT) in prostate cancer patients with seminal vesicle invasion remains insufficiently investigated. The number of studies focusing on this problem is still extremely small.Objective of this study is to evaluate the efficacy and toxicity of radiation therapy combined with hormone therapy for prostate cancer with seminal vesicle invasion.Materials and methods. From April 2016 to April 2020, 52 patients with prostate cancer (cT3bN0) received CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center. The median patient follow-up was 29.7 months (from 11.9 to 58.4 months). The mean age of patients was 65.7 years. The initial mean level of PSA was 28.7 ng/ml. Fifty (96.2 %) patients were given radiation therapy together with hormone therapy.Results. The tolerability of CRT appeared satisfactory. Grade I acute radiation-induced reactions of the urinary tract occurred in 13 (25 %) patients; grade II ones - in 2 (3.8 %) patients. Grade I acute radiation-induced reactions of the gastrointestinal tract occurred in 11 (21.5 %) patients; grade II ones - in 1 (1.9 %) patient. Grade I late complications of the urinary tract were noted in 4 (7.7 %) patients; grade II ones - in 2 (3.8 %) patients. Grade I late complications of the gastrointestinal tract were noted in 2 (3.8 %) patients; grade II ones - in 3 (5.8 %) patients.The three-year cancer-specific survival rate was 97 %; the overall survival rate was 83 %. Eight (15.4 %) patients showed prostate cancer progression. Five (9.6 %) patients experienced cancer recurrence in the form of distant bone metastases. In 1 (1.9 %) patient, disease recurrence was associated with involvement of regional lymphatic collectors and distant inguinal lymph node metastases. Local recurrence was noted in 1 (1.9 %) patient. One (1.9 %) patient developed loco-regional recurrence with distant metastasis to bones. The three-year recurrence-free survival rate was 75.6 %.Conclusion. Our study demonstrates that CRT is highly effective in prostate cancer (cT3bN0) treatment while having an acceptable level of complications.
- 10 December 2021
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 17 (4) , 94-99-99
Open AccessCombinatorial radiation therapy for prostate cancer with seminal vesicle invasion
Background. It seems advisable to investigate the feasibility of radiation therapy combined with hormone therapy to treat locally advanced prostate cancer. Combination of two ways to deliver ionizing radiation doses enables us to elevate a total tumor dose and to reduce radiation exposure to critical organs. However, the feasibility of combinatorial radiation therapy (CRT) in prostate cancer patients with seminal vesicle invasion remains insufficiently investigated. The number of studies focusing on this problem is still extremely small.Objective of this study is to evaluate the efficacy and toxicity of radiation therapy combined with hormone therapy for prostate cancer with seminal vesicle invasion.Materials and methods. From April 2016 to April 2020, 52 patients with prostate cancer (cT3bN0) received CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center. The median patient follow-up was 29.7 months (from 11.9 to 58.4 months). The mean age of patients was 65.7 years. The initial mean level of PSA was 28.7 ng/ml. Fifty (96.2 %) patients were given radiation therapy together with hormone therapy.Results. The tolerability of CRT appeared satisfactory. Grade I acute radiation-induced reactions of the urinary tract occurred in 13 (25 %) patients; grade II ones - in 2 (3.8 %) patients. Grade I acute radiation-induced reactions of the gastrointestinal tract occurred in 11 (21.5 %) patients; grade II ones - in 1 (1.9 %) patient. Grade I late complications of the urinary tract were noted in 4 (7.7 %) patients; grade II ones - in 2 (3.8 %) patients. Grade I late complications of the gastrointestinal tract were noted in 2 (3.8 %) patients; grade II ones - in 3 (5.8 %) patients.The three-year cancer-specific survival rate was 97 %; the overall survival rate was 83 %. Eight (15.4 %) patients showed prostate cancer progression. Five (9.6 %) patients experienced cancer recurrence in the form of distant bone metastases. In 1 (1.9 %) patient, disease recurrence was associated with involvement of regional lymphatic collectors and distant inguinal lymph node metastases. Local recurrence was noted in 1 (1.9 %) patient. One (1.9 %) patient developed loco-regional recurrence with distant metastasis to bones. The three-year recurrence-free survival rate was 75.6 %.Conclusion. Our study demonstrates that CRT is highly effective in prostate cancer (cT3bN0) treatment while having an acceptable level of complications.
- Open Access
- 26 April 2019
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 18 (2) , 15-21
Combined modality radiotherapy for high-risk prostate cancer. Analysis of treatment-Related complications
Purpose: to analyze toxicity of combined modality radiotherapy in high-risk prostate cancer patients.Material and methods. Short-term outcomes after combined modality radiotherapy were analyzed in 88 prostate cancer patients treated at clinic of the a.F. tsyb medical Radiological Research center between april 2016 and February 2018. the median follow-up time was 13 months (range, 3–23 months). the mean age of the patients was 64.8 years (range, 49–80 years). an initial psawas in the range of 3.5–114 ng/ml (mean 16.7 ng/ml). all patients were considered high-risk according to the d’amico classification. the patients were divided into two groups according to the sequence of combined modality radiotherapy. in group 1, the patients (n=45) received conformal EBRtto a total dose of 44–46 gy, and 2–3 weeks later, they underwent high–dose rate 192ir- brachytherapy (one single fraction of 15 gy) as a boost to EBRt. in group 2, the patients (n=43) were treated with interstitial brachytherapy followed by EBRtdelivering at total doses of 44–46 gy.Results. All patients eventually completed the combined modality radiotherapy course planned for them. acute, grade 1 genitourinary (gu) toxicities (Rtog/EoRtc) occurred in 29 (32.9 %) patients. acute gastrointestinal (gi) toxicity was grade 1 in 17 (19.3 %) and grade 2 in 2 (2.3 %) patients. late gutoxicity was grade 1 in 6 (6.8 %) and grade 2 in 3 (3.4 %) patients. an urethral stricture developed in 1 (1.1 %) patient. late gitoxicity was grade 1 in 8 (9.1 %) patients and grade 2 in 6 (6.8 %) patients.Conclusion. The preliminary results of this study suggest satisfactory tolerability of combined modality radiotherapy by prostate cancer patients. the level of acute toxicity and complications in critical organs is quite acceptable, which maintains high quality of life for patients and does not exceed the published data.
- 26 April 2019
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 18 (2) , 15-21
Open AccessCombined modality radiotherapy for high-risk prostate cancer. Analysis of treatment-Related complications
Purpose: to analyze toxicity of combined modality radiotherapy in high-risk prostate cancer patients.Material and methods. Short-term outcomes after combined modality radiotherapy were analyzed in 88 prostate cancer patients treated at clinic of the a.F. tsyb medical Radiological Research center between april 2016 and February 2018. the median follow-up time was 13 months (range, 3–23 months). the mean age of the patients was 64.8 years (range, 49–80 years). an initial psawas in the range of 3.5–114 ng/ml (mean 16.7 ng/ml). all patients were considered high-risk according to the d’amico classification. the patients were divided into two groups according to the sequence of combined modality radiotherapy. in group 1, the patients (n=45) received conformal EBRtto a total dose of 44–46 gy, and 2–3 weeks later, they underwent high–dose rate 192ir- brachytherapy (one single fraction of 15 gy) as a boost to EBRt. in group 2, the patients (n=43) were treated with interstitial brachytherapy followed by EBRtdelivering at total doses of 44–46 gy.Results. All patients eventually completed the combined modality radiotherapy course planned for them. acute, grade 1 genitourinary (gu) toxicities (Rtog/EoRtc) occurred in 29 (32.9 %) patients. acute gastrointestinal (gi) toxicity was grade 1 in 17 (19.3 %) and grade 2 in 2 (2.3 %) patients. late gutoxicity was grade 1 in 6 (6.8 %) and grade 2 in 3 (3.4 %) patients. an urethral stricture developed in 1 (1.1 %) patient. late gitoxicity was grade 1 in 8 (9.1 %) patients and grade 2 in 6 (6.8 %) patients.Conclusion. The preliminary results of this study suggest satisfactory tolerability of combined modality radiotherapy by prostate cancer patients. the level of acute toxicity and complications in critical organs is quite acceptable, which maintains high quality of life for patients and does not exceed the published data.
- Open Access
- 30 September 2017
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 13 (3) , 103-109
Palliative radiation therapy of bladder cancer
Introduction. One of the problems of urologic oncology is that patients with bladder cancer (BC) show up late for appointments, which leads to increased numbers of patients with advanced cancer stages accompanied by symptoms considerably reducing their quality of life. In most similar cases, external beam radiation therapy (EBRT) may be given with palliative intent to lessen or relieve the local symptoms of disease and to deliver the highest possible dose of radiation to bladder tumor.Objective: to assess the efficacy and toxicity of palliative EBRT in patients with BC.Materials and methods. Outcomes of palliative EBRT that had been given to 103 patients with BC were analyzed. Poor somatic health status of these patients caused by underlying disease or accompanying pathology made radical treatment impossible.Results. During EBRT treatment, hematuria was stopped in 56 (72.7 %) and reduced in 21 (27.3 %) patients. After completing EBRT, bladder pain syndrome was relieved in 13 (76.5 %) of 17 patients, but in 1 patient the pain got worse, and in 3 (17.6 %) patients no changes in this symptom occurred. Acute bladder reactions were observed in 37 (35.9 %) patients: grade I–II (RTOG) in 32 (31.1 %) patients and grade III–IV in 5 (4.8 %) patients. Acute grade I–II rectitis was noted in 10 (9.7 %) patients. Late grade I–II bladder complications (RTOG/EORTC) occurred in 16 (15.5 %) patients, and late rectal complications in 2 (1.9 %) patients. Due to relief of local symptoms and improvement of somatic health status in 16 (15.5 %) patients, it was possible to perform radical treatment for BC. At 12 months after treatment, objective tumor response was achieved in 34 (33.0 %) and stable disease in 14 (13.6 %) BC patients.Conclusion. Radiation therapy is an effective method of palliative care of patients with advanced BC and marked local symptoms. In most cases, EBRT can help stop or reduce hematuria and pain as well as improve quality of patient life. Therefore, it is necessary to develop methods of effective palliative care for patients with complicated advanced BC. A personalized approach to optimize programs palliative treatment of BC is a promising direction for further research.
- 30 September 2017
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 13 (3) , 103-109
Open AccessPalliative radiation therapy of bladder cancer
Introduction. One of the problems of urologic oncology is that patients with bladder cancer (BC) show up late for appointments, which leads to increased numbers of patients with advanced cancer stages accompanied by symptoms considerably reducing their quality of life. In most similar cases, external beam radiation therapy (EBRT) may be given with palliative intent to lessen or relieve the local symptoms of disease and to deliver the highest possible dose of radiation to bladder tumor.Objective: to assess the efficacy and toxicity of palliative EBRT in patients with BC.Materials and methods. Outcomes of palliative EBRT that had been given to 103 patients with BC were analyzed. Poor somatic health status of these patients caused by underlying disease or accompanying pathology made radical treatment impossible.Results. During EBRT treatment, hematuria was stopped in 56 (72.7 %) and reduced in 21 (27.3 %) patients. After completing EBRT, bladder pain syndrome was relieved in 13 (76.5 %) of 17 patients, but in 1 patient the pain got worse, and in 3 (17.6 %) patients no changes in this symptom occurred. Acute bladder reactions were observed in 37 (35.9 %) patients: grade I–II (RTOG) in 32 (31.1 %) patients and grade III–IV in 5 (4.8 %) patients. Acute grade I–II rectitis was noted in 10 (9.7 %) patients. Late grade I–II bladder complications (RTOG/EORTC) occurred in 16 (15.5 %) patients, and late rectal complications in 2 (1.9 %) patients. Due to relief of local symptoms and improvement of somatic health status in 16 (15.5 %) patients, it was possible to perform radical treatment for BC. At 12 months after treatment, objective tumor response was achieved in 34 (33.0 %) and stable disease in 14 (13.6 %) BC patients.Conclusion. Radiation therapy is an effective method of palliative care of patients with advanced BC and marked local symptoms. In most cases, EBRT can help stop or reduce hematuria and pain as well as improve quality of patient life. Therefore, it is necessary to develop methods of effective palliative care for patients with complicated advanced BC. A personalized approach to optimize programs palliative treatment of BC is a promising direction for further research.
- Open Access
- 1 January 2017
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 98 (6) , 303-309
SENTINEL LYMPH NODE BIOPSY IN PREVENTING REGIONAL RELAPSES IN PATIENTS WITH LOCALLY ADVANCED CUTANEOUS MELANOMA
БИОПСИЯ СТОРОЖЕВЫХ ЛИМФАТИЧЕСКИХ УЗЛОВ В ПРОФИЛАКТИКЕ РЕГИОНАРНЫХ РЕЦИДИВОВ У БОЛЬНЫХ С ЛОКАЛИЗОВАННОЙ МЕЛАНОМОЙ КОЖИ
- 1 January 2017
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 98 (6) , 303-309
Open AccessSENTINEL LYMPH NODE BIOPSY IN PREVENTING REGIONAL RELAPSES IN PATIENTS WITH LOCALLY ADVANCED CUTANEOUS MELANOMA
БИОПСИЯ СТОРОЖЕВЫХ ЛИМФАТИЧЕСКИХ УЗЛОВ В ПРОФИЛАКТИКЕ РЕГИОНАРНЫХ РЕЦИДИВОВ У БОЛЬНЫХ С ЛОКАЛИЗОВАННОЙ МЕЛАНОМОЙ КОЖИ